NASDAQ · MCRB
Seres Therapeutics, Inc.
Healthcare · Biotechnology
$1.33
Down-$0.09 (-6.77%)
Updated Nov 21, 2026, 1:58 AM
SID Score
2.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 151.06M
- P/E ratio
- 27.95
- Dividend yield
- 0.00%
- 52-week range
- $1.30 – $18.86
- Volume
- 54.69K
- Avg. volume
- 192.86K
Price performance · MCRB
MCRB price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Nov 19, 2026
MCRB closed at $1.33 after 20 trading sessions, down 36.36% for the selected period.
- Last close
- $1.33
- Period change
- -36.36%
- Period low
- $1.33
- Period high
- $2.09
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 19, 2026 | $1.47 | $1.47 | $1.31 | $1.33 | 54.69K |
| Nov 18, 2026 | $1.43 | $1.58 | $1.413 | $1.44 | 42.97K |
| Nov 17, 2026 | $1.39 | $1.50 | $1.33 | $1.41 | 55.58K |
| Nov 16, 2026 | $1.38 | $1.70 | $1.38 | $1.41 | 186.62K |
| Nov 13, 2026 | $1.38 | $1.48 | $1.3246 | $1.40 | 59.95K |
| Nov 12, 2026 | $1.48 | $1.48 | $1.30 | $1.41 | 74.19K |
| Nov 11, 2026 | $1.54 | $1.585 | $1.35 | $1.50 | 240.39K |
| Nov 10, 2026 | $1.68 | $1.74 | $1.55 | $1.56 | 39.48K |
| Nov 9, 2026 | $1.94 | $2.05 | $1.68 | $1.70 | 184.23K |
| Nov 6, 2026 | $2.13 | $2.26 | $1.96 | $1.98 | 82.28K |
| Nov 5, 2026 | $2.15 | $2.20 | $2.005 | $2.09 | 94.59K |
| Nov 4, 2026 | $1.9941 | $2.14 | $1.76 | $2.09 | 94.99K |
| Nov 3, 2026 | $1.97 | $1.98 | $1.85 | $1.96 | 53.11K |
| Nov 2, 2026 | $1.84 | $2.00 | $1.81 | $1.83 | 44.16K |
| Oct 30, 2026 | $1.92 | $1.92 | $1.75 | $1.77 | 120.11K |
| Oct 29, 2026 | $1.90 | $2.0293 | $1.81 | $1.95 | 78.51K |
| Oct 28, 2026 | $1.77 | $1.93 | $1.675 | $1.79 | 87.5K |
| Oct 27, 2026 | $2.00 | $2.00 | $1.70 | $1.80 | 165.35K |
| Oct 26, 2026 | $2.11 | $2.185 | $1.98 | $1.98 | 53.07K |
| Oct 23, 2026 | $2.13 | $2.17 | $2.00 | $2.09 | 69.71K |
Latest MCRB news
The latest Smart Investors Daily articles mentioning MCRB.
Stock researchMarket Activity · Options
Company
Market Activity
Research & News

